$11.53
Live
Insights on Iovance Biotherapeutics, Inc.
In the last 3 years, Novo Nordisk A/s has given 240.7% return, outperforming this stock by 303.3%
3.04%
Downside
Day's Volatility :3.45%
Upside
0.43%
72.16%
Downside
52 Weeks Volatility :82.49%
Upside
37.1%
Period | Iovance Biotherapeutics, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 53.27% | 1.7% | 0.0% |
6 Months | 218.21% | 11.3% | 0.0% |
1 Year | 112.52% | 5.4% | 1.3% |
3 Years | -64.59% | 13.9% | -22.1% |
Market Capitalization | 3.3B |
Book Value | $2.28 |
Earnings Per Share (EPS) | -1.89 |
PEG Ratio | 0.0 |
Wall Street Target Price | 26.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -25156.85% |
Return On Assets TTM | -39.86% |
Return On Equity TTM | -81.91% |
Revenue TTM | 1.2M |
Revenue Per Share TTM | 0.01 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -449.0M |
Diluted Eps TTM | -1.89 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.29 |
EPS Estimate Next Year | -0.71 |
EPS Estimate Current Quarter | -0.43 |
EPS Estimate Next Quarter | -0.41 |
What analysts predicted
Upside of 125.5%
Sell
Neutral
Buy
Iovance Biotherapeutics, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Iovance Biotherapeutics, Inc. | -19.41% | 218.21% | 112.52% | -64.59% | 6.26% |
Moderna, Inc. | -1.39% | 41.81% | -19.31% | -38.71% | 322.88% |
Regeneron Pharmaceuticals, Inc. | -5.68% | 13.74% | 14.81% | 80.88% | 159.02% |
Novo Nordisk A/s | -2.24% | 29.49% | 49.67% | 240.51% | 421.0% |
Vertex Pharmaceuticals Incorporated | -3.67% | 10.39% | 20.74% | 84.71% | 129.52% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Iovance Biotherapeutics, Inc. | NA | NA | 0.0 | -1.29 | -0.82 | -0.4 | NA | 2.28 |
Moderna, Inc. | 24.73 | NA | 0.0 | -6.77 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.13 | 26.13 | 1.46 | 45.02 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 48.36 | 48.36 | 2.4 | 3.34 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 29.17 | 29.17 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Iovance Biotherapeutics, Inc. | Buy | $3.3B | 6.26% | NA | 0.0% |
Moderna, Inc. | Buy | $41.3B | 322.88% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.6B | 159.02% | 26.13 | 30.14% |
Novo Nordisk A/s | Buy | $573.9B | 421.0% | 48.36 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $104.7B | 129.52% | 29.17 | 36.68% |
Vanguard Group Inc
Mhr Fund Management Llc
BlackRock Inc
State Street Corporation
Perceptive Advisors LLC
Goldman Sachs Group Inc
Iovance Biotherapeutics, Inc.’s price-to-earnings ratio stands at None
Read Moreiovance biotherapeutics is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (til). this approach, also known as adoptive t-cell therapy, was initially developed by dr. steven a. rosenberg at the national cancer institute (nci). in phase 2 clinical trials conducted at the nci, 56% and 24% of patients treated with this technology were reported by nci to have achieved objective and complete response criteria, respectively. our lead product candidate is an autologous, ready-to-infuse cell therapy, that has demonstrated distinctive efficacy in the treatment of metastatic melanoma. in addition to metastatic melanoma, carcinoma of the head and neck and cervical cancer our til therapy technology is potentially applicable to many other tumor types, including ovarian, breast, bladder, colorectal and other cancers. as we continue advancing our current clinical programs through the introduction of manufacturing and logistical
Organization | Iovance Biotherapeutics, Inc. |
Employees | 557 |
CEO | Dr. Frederick G. Vogt Esq., J.D., Ph.D. |
Industry | Health Technology |
Cerevel Therapeutics Holdings Inc
$11.53
-1.54%
Vaxcyte Inc
$11.53
-1.54%
Janux Therapeutics Inc
$11.53
-1.54%
Spdr Nuveen S&p High Yield Municipal Bond Etf
$11.53
-1.54%
Radnet Inc
$11.53
-1.54%
The St. Joe Co
$11.53
-1.54%
Harley-davidson, Inc.
$11.53
-1.54%
Vaneck Vectors Fallen Angel Hiyld Bd Etf
$11.53
-1.54%
Aurora Innovation Inc
$11.53
-1.54%